Evotec, Pfizer form alliance to promote drug discovery in France


(MENAFN) On Wednesday, Evotec, a leading German Pharmaceutical firm, announced a strategic partnership with the prominent US pharmaceutical giant Pfizer aimed at enhancing collaborative efforts in the discovery and development of new medications within France. This multi-year agreement marks a concerted effort between the two entities to initially concentrate on early-stage exploratory research targeting infectious and metabolic diseases.

Headquartered in Hamburg, Germany, Evotec disclosed that the collaborative research activities will be centered at its facilities across France, notably at the Curie complex situated in Toulouse, a state-of-the-art research center in the region. The alliance underscores Pfizer's commitment to provide financial backing for the research initiatives, underscoring Evotec's role in conducting the research. Moreover, Evotec stands to benefit from potential revenues tied to the successful outcomes of these joint research programs, reinforcing the mutual benefits and strategic alignment between the two pharmaceutical powerhouses. 

MENAFN10072024000045015682ID1108426523


MENAFN

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.